Latest filings (excl ownership)
6-K
Current report (foreign)
18 Mar 24
6-K
Current report (foreign)
26 Feb 24
6-K
Current report (foreign)
2 Feb 24
6-K
Current report (foreign)
16 Jan 24
6-K
Current report (foreign)
10 Jan 24
6-K
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
18 Dec 23
6-K
Current report (foreign)
30 Oct 23
6-K
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
4 Oct 23
UPLOAD
Letter from SEC
21 Sep 23
6-K
Current report (foreign)
20 Sep 23
CORRESP
Correspondence with SEC
15 Sep 23
UPLOAD
Letter from SEC
5 Sep 23
6-K
Current report (foreign)
14 Jul 23
6-K
Current report (foreign)
12 May 23
6-K
Current report (foreign)
18 Apr 23
20-F
2022 FY
Annual report (foreign)
18 Apr 23
6-K
Current report (foreign)
14 Mar 23
6-K
Current report (foreign)
28 Feb 23
6-K
Current report (foreign)
24 Feb 23
6-K
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules
9 Jan 23
6-K
Current report (foreign)
30 Dec 22
6-K
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
23 Nov 22
6-K
Current report (foreign)
29 Aug 22
6-K
Current report (foreign)
13 Jun 22
6-K
Current report (foreign)
9 Jun 22
6-K
Current report (foreign)
22 Apr 22
20-F
2021 FY
Annual report (foreign)
14 Apr 22
6-K
BeyondSpring Announces Organizational Streamlining
11 Jan 22
6-K
Current report (foreign)
30 Dec 21
6-K
Current report (foreign)
27 Dec 21
6-K
Current report (foreign)
1 Dec 21
6-K
BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors
10 Nov 21
6-K
Current report (foreign)
21 Sep 21
6-K
Current report (foreign)
10 Sep 21
6-K
BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China
26 Aug 21
6-K
Current report (foreign)
5 Aug 21
6-K
Current report (foreign)
4 Aug 21
6-K
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
14 Jul 21
EFFECT
Notice of effectiveness
14 Jul 21
CORRESP
Correspondence with SEC
9 Jul 21
Latest ownership filings
SC 13G/A
Ever Regal Group Ltd
14 Feb 24
SC 13G/A
Ever Regal Group Ltd
7 Apr 23
SC 13G/A
Ever Regal Group Ltd
14 Feb 23
SC 13G/A
ALLIANCEBERNSTEIN L.P.
14 Feb 22
SC 13G
Decheng Capital Management III (Cayman), LLC
14 Feb 22
SC 13G/A
Shenzhen Sangel Capital Management Ltd Co
14 Feb 22
SC 13G/A
Ever Regal Group Ltd
11 Feb 22
SC 13G/A
Ever Regal Group Ltd
16 Feb 21
SC 13G
ALLIANCEBERNSTEIN L.P.
8 Feb 21
SC 13D/A
Decheng Capital China Life Sciences USD Fund III, L.P.
8 Dec 20
SC 13D
Decheng Capital China Life Sciences USD Fund III, L.P.
27 Jul 20
SC 13G/A
BeyondSpring Inc.
10 Feb 20
SC 13G
BeyondSpring Inc.
2 Aug 19
SC 13G/A
BeyondSpring Inc.
19 Feb 19
SC 13G
BeyondSpring Inc.
14 Feb 18
SC 13G
BeyondSpring Inc.
14 Feb 18
SC 13G
BeyondSpring Inc.
14 Feb 18
SC 13G
BeyondSpring Inc.
10 Jan 18